Alaunos Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
TCRT$1.71+2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
BALANCE SHEETS
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS: | ||
| Current assets: | ||
| Cash and cash equivalents | $1,091 | $6,062 |
| Receivables | 5 | 1 |
| Prepaid expenses and other current assets | 1,659 | 2,198 |
| Total current assets | 2,755 | 8,261 |
| Property and equipment, net | — | 2 |
| Total assets | $2,755 | $8,263 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $516 | $616 |
| Accrued expenses | 176 | 1,340 |
| Total current liabilities | 692 | 1,956 |
| Total liabilities | $692 | $1,956 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity | ||
| Common stock $0.001 par value; 5,000,000 shares authorized, 1,601,252 shares issued and outstanding at December 31, 2024 and at December 31, 2023 | 2 | 2 |
| Additional paid-in capital | 922,507 | 922,072 |
| Accumulated deficit | (920,446) | (915,767) |
| Total stockholders' equity | 2,063 | 6,307 |
| Total liabilities and stockholders' equity | $2,755 | $8,263 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.